Get started
Author

Arshad M. Khanani

Observed names: A.M. Khanani, ARSHAD M. KHANANI, Arshad Khanani, Arshad M Khanani, Arshad Mohammad Khanani, Khanani AM, Khanani, A.M., Khanani, Arshad M.
Observed institutions: Texas Tech University, Cleveland Clinic, University of Nevada, Reno, Genentech, University of Michigan, Sierra Eye Associates, Texas Tech University Health Sciences Center
ORCID: 0000-0001-8928-5599
Observed ORCID: 0000-0001-8928-5599
OpenAlex ID: A5035499225
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
2023 · Jeffrey S Heier, Eleonora M Lad, et al. · The Lancet · 512
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
2023 · Arshad M Khanani, Arshad M Khanani, et al. · The Lancet · 366
PDF
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema
2019 · Jayashree Sahni, Sunil S. Patel, et al. · Ophthalmology · 285
TENAYA and LUCERNE
2024 · Arshad M. Khanani, Aachal Kotecha, et al. · Ophthalmology · 227
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
2020 · Arshad M. Khanani, Sunil S. Patel, et al. · JAMA Ophthalmology · 183
PDF
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
2023 · Arshad M. Khanani, Aamir A. Aziz, et al. · Eye · 180
PDF
Faricimab Treat-and-Extend for Diabetic Macular Edema
2023 · Tien Y. Wong, Zdenka Haskova, et al. · Ophthalmology · 177
PDF
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
2023 · Sunil S. Patel, David R. Lally, et al. · Eye · 143
PDF
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
2020 · Sara J. Haug, Doan Luong Hien, et al. · American Journal of Ophthalmology Case Reports · 142
PDF
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
2024 · Peter A Campochiaro, Robert Avery, et al. · The Lancet · 134
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab
2020 · Majid Khan, Aamir A. Aziz, et al. · Cells · 132
PDF
Review of gene therapies for age-related macular degeneration
2022 · Arshad M. Khanani, Mathew J. Thomas, et al. · Eye · 119
PDF
Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
2016 · Peter A. Campochiaro, Arshad Khanani, et al. · Ophthalmology · 116
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration
2021 · Arshad M. Khanani, Marco A. Zarbin, et al. · JAMA Ophthalmology · 113
PDF
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations
2020 · Atul Jain, Sophaktra Chea, et al. · American Journal of Ophthalmology Case Reports · 109
PDF
SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States
2019 · Arshad M. Khanani, Adrian Skelly, et al. · Ophthalmology Retina · 96
PDF
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion
2024 · Ramin Tadayoni, Liliana P. Paris, et al. · Ophthalmology · 91
PDF
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
2024 · Fernando M Penha, Maliha Masud, et al. · International Journal of Retina and Vitreous · 90
PDF
TENAYA and LUCERNE
2021 · Arshad M. Khanani, Robyn H. Guymer, et al. · Ophthalmology Science · 85
PDF
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
2020 · Anindya Samanta, Aamir A. Aziz, et al. · Asia-Pacific Journal of Ophthalmology · 82
Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study
2023 · Arshad M. Khanani, David S. Boyer, et al. · EClinicalMedicine · 76
PDF
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
2020 · Arshad M. Khanani, David Callanan, et al. · Ophthalmology Retina · 76
PDF
Retinal Fluid and Thickness as Measures of Disease Activity in Neovascular Age-related Macular Degeneration
2021 · Peter K. Kaiser, Charles C. Wykoff, et al. · Retina · 74
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid
2022 · Arshad M. Khanani, David M. Brown, et al. · Ophthalmology · 73
Angiopoietins as Potential Targets in Management of Retinal Disease
2021 · Arshad M Khanani, Matthew W Russell, et al. · Clinical ophthalmology · 64
PDF
Works count: 175
Citation count: 5,438
H-index: 35
I10-index: 84
Year
Topic
Type